#BIOCEO18: A Bright Future

“A transformative year in medicine.” That’s how BIO President and CEO Jim Greenwood recently described 2017, a year that marked government approval of new gene therapies targeting leukemia in children and young adults, lymphoma in adults and a rare form of hereditary blindness. These treatments are transforming the landscape of modern medicine, and they are also raising questions about how to ensure these more costly, one-time therapies remain accessible and affordable for pati